Germany Demand for plasma-derived medicines continues to rise, bringing renewed attention to manufacturing capacity, supply resilience and the need for stronger plasma ecosystems. As Biotest enters its next phase of growth, CEO Jörg Schüttrumpf reflects on the company’s strategic evolution, the opportunities created by its partnership with Grifols, and the role…
Germany I want Wacker Biotech to be recognised for its scientific expertise, speed, collaboration, and flexibility The expectations placed on today’s CDMOs extend far beyond manufacturing capacity, demanding scientific expertise, integrated development capabilities and resilient supply networks capable of supporting increasingly complex therapies. Wacker Biotech has responded by building a distinctive…
Europe The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for AbbVie, BeOne Medicines, CSL, Merz Therapeutics, and Novartis would love to see this realised and agree that Europe’s scientific fundamentals…
Korea James Park discusses Lotte Biologics’ strategy to establish itself as a global CDMO through dual manufacturing hubs in the US and Korea, advanced biologics and ADC capabilities, and a strong service-oriented culture. He outlines the company’s expansion plans, technological differentiation, and support for Korea’s emerging biotech ecosystem, while reflecting on…
USA Legend is looking at all ways to bring CAR-T to more patients, including allogeneic, autologous, and in vivo approaches Alan Bash, Interim CEO of Legend Biotech speaks about achieving the milestone of treating 13,000 adult patients, with relapsed or refractory multiple myeloma who have received at least 1 prior line…
USA Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs Punit Patel, President and CEO, of Zydus Americas, speaks about leading the company’s pivot from a pure-play generics business into complex generics, biosimilars and new chemical entities. Anchored by its…
Europe As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over the past five years through increased investment in R&D, manufacturing, and international expansion, the company is building on the scientific…
Germany We have set out a clear strategy, but strategy only provides direction; ultimately, trust is built through execution Europe pioneered the biosimilars industry and remains its most advanced market, yet sustaining that leadership is becoming increasingly challenging as pricing pressures, manufacturing economics and global competition reshape the sector. As Formycon…
Greece The future of Europe’s pharmaceutical industry will be shaped as much by manufacturing and industrial policy as by scientific innovation. Theodore Tryfon outlines how ELPEN is investing to strengthen healthcare resilience, expand internationally and support Greece’s emergence as a strategic pharmaceutical manufacturing hub, while reflecting on the policy choices that…
Africa Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the continent’s health agenda. Lenias Hwenda maps out why 2026 is a turning point for African patient safety — anchored by…
South Korea There is a real sense of energy and ambition across the Korean biopharma industry Sungphil Kim, General Manager of Cytiva Korea, discusses his vision for strengthening Korea’s biopharma ecosystem through customer-centricity, talent development and innovation. He highlights Cytiva’s Songdo hub, support for advanced therapies, AI and automation, and practical training…
Taiwan In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort to transform the island into a premier global hub for Cell and Gene Therapy (C>) manufacturing and development. This state-driven…
See our Cookie Privacy Policy Here
